Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V2LK
|
||||
| Former ID |
DNC012409
|
||||
| Drug Name |
6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H8N2O6
|
||||
| Canonical SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-])[N+]<br />(=O)[O-]
|
||||
| InChI |
1S/C15H8N2O6/c18-13-8-15(9-1-3-10(4-2-9)16(19)20)23-14-6-5-11(17(21)22)7-12(13)14/h1-8H
|
||||
| InChIKey |
FPLQIUAPEQSTCP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid receptor subunit alpha-1 | Target Info | Inhibitor | [1] | |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Target Info | Inhibitor | [1] | ||
| Gamma-aminobutyric acid receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Nicotine addiction | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activationR-HSA-975298:Ligand-gated ion channel transport | |||||
| GABA A receptor activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transportWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.